tldrdailynews.com logo

Lp(a) Drug Race Aims to Prove Heart Disease Prevention

1 min read
Source: STAT
Lp(a) Drug Race Aims to Prove Heart Disease Prevention
Photo: STAT
TL;DR

Rival drugmakers, led by Novartis, are sprinting to prove that lowering Lp(a) — a genetic risk factor affecting about 1 in 5 people — can prevent heart disease, a space with no approved therapies and a potential multi‑billion market as late-stage trials seek to show fewer cardiovascular events.

Topics:healthbusiness#business#cardiovascular-risk#drug-development#heart-disease-prevention#lpa#novartis
Share this article
  1. New treatments for common cardiovascular risk factor near the market, with billions at stake  STAT
  2. Why PCPs Should Check Lipoprotein(a)  Medscape
  3. Key data on a new class of cardio drugs are coming  STAT
  4. Key data on a new class of cardiovascular drugs expected soon  UA.NEWS
  5. Lipoprotein (a) goes mainstream: Test now—outcome trials coming soon  MDLinx

Want the full story? Read the original reporting

Read on STAT